Novartis Ag (NVS) Share-based Compensation (2009 - 2017)
Novartis Ag (NVS) posted Share-based Compensation of $143.0 for Q2 2010, down 5.92% sequentially from $152.0 in Q3 2009, and up 11.72% YoY from $128.0 in Q2 2009.
Novartis Ag (NVS) Share-based Compensation (2009 - 2017) Analysis & Trends
Novartis Ag has reported Share-based Compensation for 2 years, with the latest figure at $143.0 in Q2 2010.
- Quarterly Share-based Compensation rose 11.72% year-over-year to $143.0 in Q2 2010, while the trailing twelve-month figure through Jun 2010 was $540.0 (up 831.03% YoY) and the FY2017 annual result came in at $683.0 million, up 1.79% from the prior year.
- Share-based Compensation retreated to $143.0 in Q2 2010 per NVS's latest filing, from $152.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $152.0 in Q3 2009 and troughed at $128.0 in Q2 2009.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 458.00 Mn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 166.00 Mn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 298.00 Mn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | - |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 165.00 Mn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 231.00 Mn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 249.00 Mn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | - |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 683.00 Mn |
| Dec 31, 2017 | 683.00 Mn |
| Dec 31, 2016 | 671.00 Mn |
| Dec 31, 2016 | 671.00 Mn |
| Dec 31, 2015 | 773.00 Mn |
| Dec 31, 2015 | 773.00 Mn |
| Jun 30, 2010 | 143.00 |
| Jun 30, 2010 | 143.00 |
| Sep 30, 2009 | 152.00 |
| Sep 30, 2009 | 152.00 |
| Jun 30, 2009 | 128.00 |
| Jun 30, 2009 | 128.00 |